# OnCo record nct06846671 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06846671/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06846671", "NCT06846671" ;
  schema:name "A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors"@en ;
  schema:alternateName "CaDAnCe-302"@en ;
  schema:description "A phase 3 trial of Bendamustine, Idelalisib, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06846671/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06846671> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-04-10" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/idelalisib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/beone/> .